|Mr. Philip Astley-Sparke||Exec. Chairman, Sec. & Treasurer||338.45k||N/A||1971|
|Dr. Robert Coffin||Pres, CEO & Director||536.29k||N/A||1965|
|Dr. Colin Love||Chief Operating Officer||413.62k||N/A||1958|
|Dr. Pamela Esposito||Chief Bus. Officer||351.45k||N/A||1974|
|Stephen Gorgol||Chief Accounting Officer||N/A||N/A||N/A|
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.